360 ONE Asset, an asset management firm, has acquired a stake in OneSource Specialty Pharma, a contract development and manufacturing organisation (CDMO) specialising in biologics, complex injectables, and drug-device combinations.
The deal involves buying out an existing investor’s stake in the company. 360 ONE did not provide information on the size of the investment, the valuation, or the investor from whom it is acquiring the interest.
Tarun Sharma, Fund Manager (Healthcare and Consumer) at 360 ONE Asset, said, “We are delighted to back OneSource and its stellar team that has built a wide portfolio of capabilities. The company’s leadership in large molecules, complex injectables, and drug-device combinations positions it perfectly for the next phase of growth. We look forward to collaborating with OneSource as they continue their journey of innovation and global expansion,”
“OneSource has established itself as a trusted development and manufacturing partner for top pharmaceutical companies worldwide. Our expertise in niche and complex dosage forms, along with our track record of superior compliance, allows us to provide an integrated, one-stop solution to our global clients. We are glad to welcome 360 ONE Asset as an investor who aligns with our mission to scale further,” said Neeraj Sharma, CEO of OneSource Specialty Pharma.
OneSource was formed after the National Company Law Tribunal (NCLT) approved the merger of Strides Pharma Science, Steriscience Specialties, and the high-end biologics operations previously under Stelis Biopharma, a move supported by a fresh ₹801 crore ($95 million) equity infusion. The company was valued at a pre-money equity valuation of $1.65 billion at the time.
OneSource is one of the few companies from India that has the expertise to develop and manufacture complex products such as GLP-1 drugs and novel biologics, further strengthening its leadership in the space. OneSource has five highly automated manufacturing plants, including four US FDA-approved sites with impeccable compliance records, and a team of over 1,200 employees, including 100+ scientists and techno-commercial experts.
